We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Ask ADVFN Intelligence (AI)
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of...
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology...
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant...
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP...
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage...
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.21 | 1.59211523882 | 13.19 | 15 | 13.07 | 1013180 | 13.49062375 | CS |
| 4 | 0.21 | 1.59211523882 | 13.19 | 15.8 | 13 | 591103 | 13.95761921 | CS |
| 12 | 2.15 | 19.1111111111 | 11.25 | 16.1 | 10.32 | 505498 | 13.58239566 | CS |
| 26 | 2.24 | 20.0716845878 | 11.16 | 16.1 | 10.29 | 498967 | 12.90198096 | CS |
| 52 | -4.2 | -23.8636363636 | 17.6 | 19.62 | 10.29 | 467682 | 13.76855972 | CS |
| 156 | -1.89 | -12.3610202747 | 15.29 | 36.64 | 3.965 | 633636 | 19.18173647 | CS |
| 260 | -9.1 | -40.4444444444 | 22.5 | 43.92 | 3.965 | 459890 | 19.84090582 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
